BCD-100 - first russian PD-1 inhibitor

• Main Authors: S A Tyulyandin, M Yu Fedyanin, T Yu Semiglazova, V M Moiseenko, S V Odintsova, B Ya Alekseev, R A Ivanov, M S Shustova
• Format: Article
• Language: Russian
• Published: IP Habib O.N. 2017-09-01
• Series: Современная онкология
• Subjects: bcd-100; pd-1; oncological diseases; immunotherapy; monoclonal antibody; pharmacokinetics; pharmacodynamics; safety; efficacy; immunogenicity; dose-limiting toxicity
• Online Access: https://modernonco.orscience.ru/1815-1434/article/viewFile/27133/pdf

Purpose. To evaluate pharmacokinetics, pharmacodynamics, safety, immunogenicity and efficacy of intravenous infusions of BCD-100 (JSC “BIOCAD”, Russia) in increasing doses. Patients (materials) and methods. Patients with advanced malignant tumors of various localizations without severe somatic pathology were consistently included in cohorts receiving the BCD-100 drug in monotherapy at different doses (0.3, 1.0, 3.0 and 10 mg/kg) every 2 weeks for at least 85 days. Safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of the therapy were assessed. Results. 15 patients were included in the study. The vast majority of adverse events were represented by deviations in the results of laboratory tests of 1-2 grade, there was only one confirmed case of dose-limiting toxicity (autoimmune thyroiditis of 2 grade). Pharmaco kinetic parameters were standard for drug based on monoclonal antibodies of class IgG1. The saturation of PD-1 receptors by BCD-100 was high (90-100%) at all dose levels. 1 partial response to antitumor therapy and 3 stabilization cases according to irRC criteria were registered. conclusion. BCD-100 demonstrated a favorable profile of safety and immunogenicity, expected pharmacokinetic parameters allowing the drug to be administered once every 2 or 3 weeks, high pharmacodynamic parameters and the presence of antitumor activity.